Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CK0803 in Amyotrophic Lateral Sclerosis
NCT05695521Phase 1Active, not recruiting
- Start
- Apr 2023
- Primary completion
- May 2027
- Modality
- Regulatory T Cells (Tregs)
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in amyotrophic lateral sclerosis (ALS) comparing CK0803 with Placebo (2 arms). Primary endpoints: Treatment Limiting Toxicity at 28 days and Combined assessment of function and survival at 24 weeks. Started Apr 2023; status: active, not recruiting.
02
Drugs
CK0803
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NCT05695521.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05695521.